Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists - Wikidata - awgldk - TriplyDB

Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists

Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists

http://www.wikidata.org/entity/Q26823085

about

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg.The Predictive Role of Tooth Extractions, Oral Infections, and hs-C-Reactive Protein for Mortality in Individuals with and without Diabetes: A Prospective Cohort Study of a 12 1/2-Year Follow-Up Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.Factors associated with no apparent coronary artery disease in patients with type 2 diabetes mellitus for more than 10 years of duration: a case control study.Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.The emerging role of metformin in gestational diabetes mellitus.Association Between Subtotal Gastrectomy with Billroth II Anastomosis and Coronary Heart Disease.The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials.Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats.Effect of dipeptidyl peptidase 4 inhibitors on acute and subacute models of inflammation in male Wistar rats: An experimental study.A Review on the Phytochemistry, Pharmacology, Pharmacokinetics and Toxicology of Geniposide, a Natural Product.Liraglutide mitigates TNF-α induced pro-atherogenic changes and microvesicle release in HUVEC from diabetic women.Efficacy and Safety of Ranolazine in Diabetic Patients: A Systematic Review and Meta-analysis.Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea.Long-Acting GLP-1 Receptor Agonist Exenatide Influence on the Autonomic Cardiac Sympatho-Vagal Balance.Chemistry and Hypoglycemic Activity of GPR119 Agonist ZB-16

P2860

Q26749495-79368BC6-8CE6-4E37-B528-DC591A9B5F75 Q26799389-27B089B1-D4B4-4F4A-A6F9-86EA66119167 Q28078225-EA6FD90B-8C26-4CEB-9388-CACAFA077024 Q33750634-9E76EC9C-B635-4414-AD21-CF898FA2491E Q33872769-584DAD74-44BC-4600-A7C5-CF81F0BE7D0E Q36023385-65F4FA63-B830-4568-A6D8-E7BEA58CE601 Q36235047-A27170EE-C78B-4608-ADF3-BAC5DC5D2DE4 Q38702260-A4DF8069-D6A9-4A00-9C38-47BA9F769B1D Q38996030-303C44D5-79EC-4C9F-BBB8-B37B1D15F8DE Q39025644-9384CFF0-6448-4B7C-9BD9-953923F48CA4 Q39140294-53FE3D60-4463-426C-BCF9-29374687CEF9 Q39870068-EBE805C2-61F9-4A3C-B3E9-E9FEC1A4767A Q41811427-802D9C01-D466-4DBA-98B8-5B5CDF7C22BE Q42319765-278D4633-3422-46FC-8C9D-18AB0D6893BD Q46289886-F459615F-1A2D-4FAC-A307-A4B4F2EB7B29 Q48329387-225EFB20-C3D1-4568-8C0E-3A9E96DAC6BE Q49909252-E1371AFE-2B7F-465D-B9C5-C2A4F5738947 Q54993721-DEDE105C-945B-402B-9CC4-CD2A27DCB71C Q55090958-925A243A-0026-4769-AD00-5902C8B2F4EE Q57072608-E227D3D2-8F63-4327-AE3F-0201748EE3B5

P2860

Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists

http://www.wikidata.org/entity/Q26823085

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists

@ast

Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists

@en

Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists

@nl

type

label

Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists

@ast

Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists

@en

Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists

@nl

prefLabel

Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists

@ast

Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists

@en

Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists

@nl

P1433

Q26823085-9FD10752-5C40-4014-9137-51662A8C4BA0

P1476

Q26823085-DA8122DB-38FA-4B9E-90A9-54BBB542B1CD

P2093

Q26823085-48B3F00F-EDE0-4DBF-B03C-34122E21B1DA

P275

Q26823085-A2CBA6C9-4A27-435C-855F-853DFC7A43B3

P2860

Q26823085-000E8D46-A7B7-4A1A-9C0A-45815DEB1AED

Q26823085-0386EF44-A230-4D28-92ED-7A9F4560C3FB

Q26823085-04369B39-FA16-4098-80ED-8959C69E6AAD

Q26823085-0668DA4E-48D4-4725-AD1C-A74802598008

Q26823085-0763528D-8856-47F9-A3B6-31F70B237B29

Q26823085-0801A342-0016-46FC-B587-E3CAF02D4884

Q26823085-09531DE5-4865-4858-8742-E1EB08604008

Q26823085-0DD95480-8CA7-4623-BDA9-D9EC751DCA01

Q26823085-1621C79C-1AAF-4E84-A9F8-12D02917B86F

Q26823085-16AE8D0B-DC43-4BDA-9EB8-03B980F46BBD

P2888

Q26823085-220A0538-C500-4FD5-819A-C54FB9117BD7

P304

Q26823085-CCF44EE2-70F2-4DF9-AA12-98CECE90022B

P31

Q26823085-AECF2A2B-75D8-4053-B5B0-853A32FC651D

P3181

Q26823085-B3804E2B-4050-491E-8AEA-0BE99AA9B93D

P356

Q26823085-8A192175-0B3F-44A1-8477-E2686A31A012

P407

Q26823085-37982B26-AFF1-4803-8624-2FC27BFBE093

P478

Q26823085-4E47B944-107E-4080-AF85-50100B0CA10A

P50

Q26823085-D88E68E4-42CD-4852-BE57-08068EF37131

P5008

Q26823085-B0F9C26A-4AC8-42BF-8A42-A2E1FE009E4A

P577

Q26823085-85D24391-C0A9-44EF-93D0-F2BCB36B0EEE

P5875

Q26823085-45B69EBE-CA9D-4B0C-9224-5304DA562551

P6179

Q26823085-160594A1-489D-4DBF-8309-21042C952A4E

P698

Q26823085-FCD0355F-FCB9-4BA3-903F-D2736681BEDB

P921

Q26823085-0C17ABAE-1808-4BFA-B4A9-938290F021BD

Q26823085-4184FE7D-31E6-4072-9760-6324BFA95A42

Q26823085-80FEDB06-F17E-4F5D-BCA3-A31BB40E5D58

Q26823085-B43CB915-BDFD-4A63-800D-649A2186CC42

Q26823085-FDEB900E-A4D2-4F50-97A0-6A4EA9DA6324

Q26823085-FFF219B9-9191-40E4-BC70-6303CDCD7E94

P932

Q26823085-F1129694-756E-42E1-A68B-91584E0850FF

P3181

P356

S12933-014-0142-7

P1433

Cardiovascular Diabetology

P1476

Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists

@en

P2093

Francisco Kerr Saraiva

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

Biology of incretins: GLP-1 and GIP

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.

Glucagon-like peptide-1 increases beta-cell glucose competence and proliferation by translational induction of insulin-like growth factor-1 receptor expression.

The glucagon-like peptides.

P2888

s12933-014-0142-7

P304

142

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2109304

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/S12933-014-0142-7

http://www.w3.org/2001/XMLSchema#string

P407

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Andrei C. Sposito

P5008

P577

2014-10-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267740019

http://www.w3.org/2001/XMLSchema#string

P6179

1032376861

http://www.w3.org/2001/XMLSchema#string

P698

25338737

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

cell surface receptor

type-2 diabetes

cardiovascular disease

membrane proteins

maturity-onset diabetes of the young

P932

4216654

http://www.w3.org/2001/XMLSchema#string